Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Esketamine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Esketamine | hsa00310 | Lysine degradation | 1.53E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Esketamine | hsa00562 | Inositol phosphate metabolism | 2.54E-03 | 4 | P27987, Q13572, Q96PE3, P42338 | ITPKB, ITPK1, INPP4A, PIK3CB | More | | Esketamine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | Esketamine | hsa03010 | Ribosome | 2.60E-08 | 8 | Q07020, P46778, P61513, Q02878, P35268, P63173, P27635, P62249 | RPL18, RPL21, RPL37A, RPL6, RPL22, RPL38, RPL10, RPS16 | More | | Esketamine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Esketamine | hsa03040 | Spliceosome | 3.94E-04 | 8 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q01130, O43447 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS2, PPIH | More | | Esketamine | hsa04014 | Ras signaling pathway | 3.62E-02 | 5 | P42338, P49767, P0DP23, P63218, P50151 | PIK3CB, VEGFC, CALM1, GNG5, GNG10 | More | | Esketamine | hsa04020 | Calcium signaling pathway | 5.15E-05 | 8 | P27987, P21796, Q16566, P30679, O15399, P0DP23, P23634, P49767 | ITPKB, VDAC1, CAMK4, GNA15, GRIN2D, CALM1, ATP2B4, VEGFC | More | | Esketamine | hsa04024 | cAMP signaling pathway | 1.49E-02 | 5 | P42338, P0DP23, P23634, Q16566, O15399 | PIK3CB, CALM1, ATP2B4, CAMK4, GRIN2D | More | | Esketamine | hsa04070 | Phosphatidylinositol signaling system | 1.49E-03 | 5 | P0DP23, P42338, Q96PE3, Q13572, P27987 | CALM1, PIK3CB, INPP4A, ITPK1, ITPKB | More | | Esketamine | hsa04371 | Apelin signaling pathway | 7.45E-03 | 5 | P63218, P50151, Q13485, Q16566, P0DP23 | GNG5, GNG10, SMAD4, CAMK4, CALM1 | More | | Esketamine | hsa04613 | Neutrophil extracellular trap formation | 4.20E-02 | 5 | P04908, Q93077, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | Esketamine | hsa04664 | Fc epsilon RI signaling pathway | 2.32E-02 | 3 | P42338, P07948, P09917 | PIK3CB, LYN, ALOX5 | More | | Esketamine | hsa04666 | Fc gamma R-mediated phagocytosis | 4.10E-02 | 3 | P07948, P42338, P23528 | LYN, PIK3CB, CFL1 | More | | Esketamine | hsa04713 | Circadian entrainment | 8.43E-03 | 4 | O15399, P0DP23, P63218, P50151 | GRIN2D, CALM1, GNG5, GNG10 | More | | Esketamine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Esketamine | hsa04720 | Long-term potentiation | 1.63E-02 | 3 | Q16566, P0DP23, O15399 | CAMK4, CALM1, GRIN2D | More | | Esketamine | hsa04724 | Glutamatergic synapse | 4.10E-02 | 3 | O15399, P63218, P50151 | GRIN2D, GNG5, GNG10 | More | | Esketamine | hsa04725 | Cholinergic synapse | 5.94E-03 | 4 | P63218, P50151, Q16566, P42338 | GNG5, GNG10, CAMK4, PIK3CB | More | | Esketamine | hsa04726 | Serotonergic synapse | 1.52E-02 | 4 | P63218, P50151, P33260, P09917 | GNG5, GNG10, CYP2C18, ALOX5 | More | | Esketamine | hsa04728 | Dopaminergic synapse | 4.47E-02 | 4 | P63218, P50151, P0DP23, O00327 | GNG5, GNG10, CALM1, ARNTL | More | | Esketamine | hsa04925 | Aldosterone synthesis and secretion | 3.14E-02 | 3 | P0DP23, Q16566, P23634 | CALM1, CAMK4, ATP2B4 | More | | Esketamine | hsa04926 | Relaxin signaling pathway | 5.70E-03 | 5 | P42338, P63218, P50151, P49767, P30679 | PIK3CB, GNG5, GNG10, VEGFC, GNA15 | More | | Esketamine | hsa04932 | Non-alcoholic fatty liver disease | 3.62E-02 | 3 | P49841, Q16718, O14521 | GSK3B, NDUFA5, SDHD | More | | Esketamine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Esketamine | hsa05017 | Spinocerebellar ataxia | 5.94E-03 | 4 | Q8TB72, O15399, P42338, P21796 | PUM2, GRIN2D, PIK3CB, VDAC1 | More | | Esketamine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Esketamine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Esketamine | hsa05034 | Alcoholism | 3.62E-02 | 5 | O15399, Q16566, P0DP23, P63218, P50151 | GRIN2D, CAMK4, CALM1, GNG5, GNG10 | More | | Esketamine | hsa05163 | Human cytomegalovirus infection | 4.19E-02 | 5 | P42338, P63218, P50151, P0DP23, P30101 | PIK3CB, GNG5, GNG10, CALM1, PDIA3 | More | | Esketamine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.19E-02 | 5 | P42338, P63218, P50151, P07948, P0DP23 | PIK3CB, GNG5, GNG10, LYN, CALM1 | More | | Esketamine | hsa05170 | Human immunodeficiency virus 1 infection | 3.27E-02 | 6 | P42338, P63218, P50151, P0DP23, P30101, P23528 | PIK3CB, GNG5, GNG10, CALM1, PDIA3, CFL1 | More | | Esketamine | hsa05171 | Coronavirus disease - COVID-19 | 6.67E-08 | 8 | P62249, Q02878, P27635, Q07020, P46778, P35268, P61513, P63173 | RPS16, RPL6, RPL10, RPL18, RPL21, RPL22, RPL37A, RPL38 | More | | Esketamine | hsa05204 | Chemical carcinogenesis | 4.62E-02 | 2 | P78417, P33260 | GSTO1, CYP2C18 | More | | Esketamine | hsa05214 | Glioma | 2.32E-02 | 3 | P0DP23, Q16566, P42338 | CALM1, CAMK4, PIK3CB | More | | Esketamine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | |